Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

• Status: Recruiting
• Trial end date: 2025-04-01

Summary

The primary objective of the trial is to evaluate the antitumor activity of atezolizumab and rucaparib in patients with selected advanced solid tumors as measured by the Overall Response Rate

• Phase: Phase 2

Details

• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
• Treatments: Antibodies; Antibodies, Monoclonal; Atezolizumab; Poly(ADP-ribose) Polymerase Inhibitors; Rucaparib